The authors of the original article “CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.” (Biosci Rep (2021) 41(10), https://doi.org/10.1042/BSR20211103) would like to correct Table 2. Due to their negligence, they had switched the number of high CDKN2A expression deaths with that of survivals in Table 2. This reversal in figures is corrected in this Correction.
Table 2
Demographic and clinicopathological parameters of patients with hepatocellular carcinoma (data from 35 clinical patients)
| Clinicopathological factor . | Number of cases(n = 35) . | CDKN2A . | P . | |
|---|---|---|---|---|
| . | . | High expression . | Low expression . | . |
| Age | ||||
| <55 | 7 | 5 | 2 | 0.156 |
| ≥55 | 28 | 19 | 9 | |
| Gender | ||||
| Male | 20 | 14 | 6 | 0.892 |
| Female | 15 | 10 | 5 | |
| TNM stage | ||||
| I-II | 16 | 11 | 5 | 0.053 |
| III-IV | 19 | 13 | 6 | |
| Grade | ||||
| I-II | 14 | 10 | 4 | 0.684 |
| III-IV | 21 | 14 | 7 | |
| Survival status | ||||
| Death | 16 | 14 | 2 | 0.035 |
| Survival | 19 | 10 | 9 | |
| Clinicopathological factor . | Number of cases(n = 35) . | CDKN2A . | P . | |
|---|---|---|---|---|
| . | . | High expression . | Low expression . | . |
| Age | ||||
| <55 | 7 | 5 | 2 | 0.156 |
| ≥55 | 28 | 19 | 9 | |
| Gender | ||||
| Male | 20 | 14 | 6 | 0.892 |
| Female | 15 | 10 | 5 | |
| TNM stage | ||||
| I-II | 16 | 11 | 5 | 0.053 |
| III-IV | 19 | 13 | 6 | |
| Grade | ||||
| I-II | 14 | 10 | 4 | 0.684 |
| III-IV | 21 | 14 | 7 | |
| Survival status | ||||
| Death | 16 | 14 | 2 | 0.035 |
| Survival | 19 | 10 | 9 | |
© 2022 The Author(s).
2022
This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
